Two Sequential Studies for Primary Peritoneal Carcinoma: Induction with Weekly Cisplatin Followed by either Cisplatin-Doxorubicin-Cyclophosphamide or Paclitaxel-Cisplatin

By Piver M.S.   Eltabbakh G.H.   Hempling R.E.   Recio F.O.   Blumenson L.E.  

Gynecologic Oncology, Vol. 67, Iss. 2, 1997-11 ,pp. : 141-146

Elsevier

Access to resources Recommend Favorite

Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

By Isik Metin  

Medical Oncology, Vol. 28, Iss. 2, 2011-06 ,pp. : 591-596

Humana Press, Inc

Access to resources Recommend Favorite

Correlation between Extreme Drug Resistance Assay and Response to Primary Paclitaxel and Cisplatin in Patients with Epithelial Ovarian Cancer

By Eltabbakh G.H.   Piver M.S.   Hempling R.E.   Recio F.O.   Lele S.B.   Marchetti D.L.   Baker T.R.   Blumenson L.E.  

Gynecologic Oncology, Vol. 70, Iss. 3, 1998-09 ,pp. : 392-397

Elsevier

Access to resources Recommend Favorite

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis

By Takano Masashi   Sugiyama Toru   Yaegashi Nobuo   Suzuki Mitsuaki   Tsuda Hiroshi   Sagae Satoru   Udagawa Yasuhiro   Kuzuya Kazuo   Kigawa Junzo   Takeuchi Satoshi   Tsuda Hitoshi   Moriya Takuya   Kikuchi Yoshihiro  

International Journal of Clinical Oncology, Vol. 12, Iss. 4, 2007-08 ,pp. : 256-260

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

By Campos Susana  

The Women's Oncology Review, Vol. 5, Iss. 2, 2005-06 ,pp. : 105-107

Informa Healthcare

Access to resources Recommend Favorite